ClinicalTrials.gg
RecruitingNCT07225101Updated Nov 5, 2025

Evaluation of the Efficacy of STRATAFIX for Neurosurgical Cranial and Spine Procedures

A Phase 4 interventional study of STRATAFIX PDS and Monocryl suture in Wound Closure, Brain Tumor Adult and Spine, sponsored by University of Michigan. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-05.

Sponsored by University of Michigan · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
160
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 76 studies in Hemorrhagic Stroke with a site in United States — 22 open to participants now, 28 under way, 1 of them phase 3. Hemorrhagic Stroke · United States.

Planned enrollment
13th of 57
160 · median 30
Started
2025
with 6 others
Phase 4
2 of 76
1 open now
Primary completion
2026-06
later than 4 of 27 live
Registered
72nd of 76
by date

Among the 76 studies in Hemorrhagic Stroke with a site in United States, this one is the 13th largest by planned enrollment of the 57 interventional ones that give a count, is one of 7 that started in 2025, is one of 2 in phase 4, reaches primary completion later than 4 of the 27 other live ones, and was the 72nd registered.

Hemorrhagic Stroke

234 studies on the registry are indexed under Hemorrhagic Stroke; 94 are open to participants now.

Browse Hemorrhagic Stroke studies →

Open to participants now

22 of the 76 studies in Hemorrhagic Stroke with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 62 Hemorrhagic Stroke studies recruiting now, 36 (58%) set no upper age limit and 7 (11%) stop at 75 or younger; 5 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Hemorrhagic Stroke with a site in United States, or all of them as a file.
02

Study summary

This research is studying a device already approved by the Food and Drug Administration (FDA) to treat wound closures. Researchers are studying a large group of people to continue to learn information about the safety of the STRATAFIX suture and how people's bodies react to using it over a long period of time. This research will provide additional information about using STRATAFIX sutures to close surgical wounds.

03

Conditions studied

  • Wound Closure
  • Brain Tumor Adult
  • Spine
  • Neurovascular
  • Hemorrhagic Stroke, Intracerebral
  • Traumatic Brain Injury

Keywords

  • Superficial surgical site infection
  • Suture material
  • Wound closure techniques
  • brain tumor
  • spine
  • spine trauma
  • neurosurgery
  • hemorrhagic stroke
  • traumatic brain injury
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Elective or emergent surgical approaches for cranial or spine neurosurgical approaches, requiring sutures for wound closure, requiring multilayer wound closure

Exclusion criteria

Exclusion Criteria:

  • Patients with prior surgical wound dehiscence or infection
  • Patients with allergy to suture material
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    STRATAFIX PDS and Monocryl suture

    All participants enrolled will have their scheduled surgery as planned with their wound closed using STRATAFIX.

    Device: STRATAFIX PDS and Monocryl suture

Interventions

  • DeviceSTRATAFIX PDS and Monocryl suture

    STRATAFIX, suture employs a novel incorporation of barbed components to suture resulting in tension holding closure with long-lasting absorbable suture.

06

What researchers measure

Primary outcomes

  1. Wound complications Bates-Jensen Wound Assessment Tool (BWAT) score

    The BWAT evaluates 13 categories including size, depth, edges, undermining, necrotic tissue type and amount, exudate type and amount, skin color, peripheral tissue, granulation tissue and epithelialization with a total score of 65. Minimal severity scores are 10-20 out of the total of 65 with good interrater reliability and validation in a variety of clinical environments. Wounds with scores \<10 will be considered healed.

    Time frame: 1 month

Secondary outcomes

  1. Wound complications Bates-Jensen Wound Assessment Tool (BWAT) score

    The BWAT evaluates 13 categories including size, depth, edges, undermining, necrotic tissue type and amount, exudate type and amount, skin color, peripheral tissue, granulation tissue and epithelialization with a total score of 65. Minimal severity scores are 10-20 out of the total of 65 with good interrater reliability and validation in a variety of clinical environments. Wounds with scores \<10 will be considered healed. Scores will be separated into specific patient subgroups (e.g., spine procedures vs. cranial procedures, younger vs. older patients)

    Time frame: 3 and 6 months

  2. The Wound-Quality of Life (QOL) questionnaire score

    This is a 17-point scale with 5 choices each ranging from 17-85. Higher scores indicate worse quality of life.

    Time frame: 1, 3 and 6 months

  3. Intraoperative time required for wound closure

    Time for intraoperative wound closure will be monitored. Wound closure technique will be video recorded.

    Time frame: Immediately following surgery

  4. Percent of participants positive for superficial surgical site infection (SSI)

    Assessed using a culture or polymerase chain reaction

    Time frame: Up to six months

  5. Number of case deviations and descriptions from prescribed suturing paradigm

    A quantification and description for additional suture material required for surgical procedures will be monitored.

    Time frame: Immediately following surgery

  6. Liker scale of patient satisfaction with wound

    10 point subjective scale indicating patient satisfaction with wound

    Time frame: 1, 3 and 6 months

  7. Wound imaging at perioperative followup

    Wound pictures during followup period.

    Time frame: 1, 3 and 6 months

  8. Wound revision strategy

    Description of any wound revision strategies and timing

    Time frame: up to 6 months

07

Study locations

1 of 1 sites recruiting
  • University of Michigan Health Sparrow
    Lansing, Michigan 48912, United States
    Recruiting
    • Karen Sagher · Contactkfrisch@med.umich.edu · 734-232-4843
    • Michael Karsy, MD, PhD, MSc · Principal investigator
    • Nasser M Yaghi, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Undecided — Unclear if manuscript will be published in an ICMJE journal and data from this study are restricted from the University of Michigan Data Use Committee

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Jun 2026, 7 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2025
First posted
Nov 5, 2025
StartActual
Nov 1, 2025
Primary completionEst.
Jun 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Nov 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07225101
Collaborators
Johnson & Johnson
Responsible party
Michael Karsy (Assistant Clinical Professor of Neurosurgery, University of Michigan) — Principal investigator
First posted
Nov 5, 2025
Start date
Nov 1, 2025
Primary completion
Jun 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 5, 2025

Study contacts

Karen Sagher
Contact
kfrisch@med.umich.edu
734-232-4843
Michael Karsy, MD, PhD, MSc
principal investigator · University of Michigan

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion